


1/8


**Dimeric ORF2.1 antigen of hepatitis E virus**



**Figure 1**

2/8

### Multimeric antigen of hepatitis A virus




**Figure 2**

3/8

**Virus-like particle (VLP) of duck hepatitis B virus.**

**A. Use of anti-DHBV bridge**




**Figure 3**

4/8

**Virus-like particle (VLP) of duck hepatitis B virus.**

**B Use of anti-analyte bridge**




**Figure 4**

5/8

**Monomeric antigen with second binding site as bridge.**

**A. Use of second epitope on the analyte antigen**




**Figure 5**

6/8

**Monomeric antigen with second binding site as bridge.**


**B. Use of fusion protein such as MBP with analyte antigen**



**Figure 6**

7/8


**Monomeric antigen with ligand binding site as bridge.**



**Figure 7**

8/8

### Multimeric antigen of hepatitis A virus.



**Figure 8**